You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
-
2025
12-06
New Progress of the KUNPENG Study: Research Findings on Vebreltinib for Advanced NSCLC with MET Amplification Presented at the 2025 ESMO Asia Congress
The ESMO Asia Congress 2025 is ongoing in Singapore from December 5 to 7, 2025. At this annual meeting, Avistone announced the results of the Phase II clinical trial "Vebreltinib for the Treatment of Advanced NSCLC with MET Amplification (the KUNPENG Study)", which was led by Professor Wu Yilong from the Guangdong Lung Cancer Institute.
View Details
-
2025
12-05
[ESMO ASIA 2025 Express] Avistone Unveils Groundbreaking Research Findings: New Evidence for Treating MET-Altered NSCLC Patients with EGFR-TKI Resistance
The 2025 European Society for Medical Oncology Asia Congress (ESMO ASIA) was held in Singapore from December 5 to 7, 2025. At this congress, data from the Phase Ib/II KYLIN-1 study—initiated by Avistone Biotech and led by Professor Zhou Caicun of Shanghai East Hospital—was presented in poster format (Abstract 998P)[1]. The KYLIN-1 study focuses on the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients with MET amplification or overexpression who have previously failed EGFR-TKI therapy, using the combination of Vebreltinib and Andamertinib (PLB1004). It demonstrated the consistency of MET amplification and overexpression results across different detection methods, the excellent efficacy and safety profiles of the dual-target combination regimen, as well as the potential of MET overexpression (IHC3+) as a promising biomarker.
View Details
-
2025
10-18
Avistone Presents Latest Clinical Studies of Andamertinib (PLB-1004) in Advanced NSCLC with EGFR Exon 20 Insertions at 2025 ESMO
The 2025 European Society for Medical Oncology (ESMO) Congress is held in Berlin, Germany, from October 17 to 21 (local time). Beijing Avistone Biotechnology Co., Ltd. ("Avistone") announced the latest study results of Andamertinib (PLB-1004) in advanced non-small-cell lung cancer with EGFR exon 20 insertions after platinum-based chemotherapy or immunotherapy at this year's congress.
View Details
